Medicines Discovery Catapult finalist for the Bionow Technical Service Award

Medicines Discovery Catapult

Yesterday (28th November 2019) Medicines Discovery Catapult (MDC) was recognised at the Bionow Annual Awards 2019, being a finalist for the Bionow Technical Service Award for their Pre-clinical Imaging service.

Congratulations to Evotec who were the eventual Award winner!

MDC were selected as finalists for the award for their demonstration of an innovative approach which serves a human healthcare need, and provides an innovative solution to a particular problem encountered within the industry.

Shortlisted alongside Alcyomics, CatSci and Evotec, MDC was recognised within the category for their commitment, professionalism, creativity and success of support to businesses in the biomedical sector through their world-class imaging service.

High-cost equipment, specialist expertise, animal husbandry requirements, and significant regulatory challenges represent high barriers to entry in this area. Access to these platforms has been highly challenging for UK drug discovery innovators.

MDC has worked with Alderley Park Limited to establish expertise and technologies, based in a state-of-the-art pre-clinical facility, for multi-parametric pre-clinical imaging. Led by scientists with extensive pharma experience, the high-quality service focusses on accelerating drug discovery projects towards patients and helping UK SMEs, pharma, research charity and academic innovators.

The Bionow Technical Services Award nomination highlights the important role MDC’s pre-clinical imaging services and know-how plays for UK Biotech, Pharma and SMEs to overcome prohibitive set-up costs and advance therapies to market faster.

Find out more about MDC’s Pre-clinical Imaging service >